[{"orgOrder":0,"company":"Amniotics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PulmoStem","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Amniotics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amniotics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amniotics \/ Inapplicable"},{"orgOrder":0,"company":"Amniotics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"PulmoStem","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Amniotics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amniotics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Amniotics \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Amniotics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : The primary objective of the study is to evaluate the safety and tolerability of intravenous dosing of PulmoStem (amniopul-02) in patients with severe lower respiratory tract infections, including COVID-19, Influenza A, Metapneumovirus and Respiratory Sy...

                          Product Name : PulmoStem

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          November 10, 2022

                          Lead Product(s) : PulmoStem

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IOPC
                          Not Confirmed
                          IOPC
                          Not Confirmed

                          Details : The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid. Lead candidate PulmoStem™, a first-in-class treatment for pulmonary disease is scheduled...

                          Product Name : PulmoStem

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 07, 2021

                          Lead Product(s) : PulmoStem

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : $6.9 million

                          Deal Type : Public Offering

                          blank